Table 1.
Comparison of clinical indices and pathological data between NAC non-effectual group and NAC effectual group.
Characteristics | NAC non-effectual group n = 5 | NAC effectual group n = 18 | p-value | |
---|---|---|---|---|
Age (years, mean ± SD) | 52.80 ± 7.16 | 50.50 ± 10.41 | 0.58 | |
BMI (kg/m2, mean ± SD) | 21.99 ± 3.10 | 22.74 ± 3.20 | 0.65 | |
Menopausal status | Premenopausal | 2 | 10 | 0.64 |
Postmenopausal | 3 | 8 | ||
Pathological Type (tumor size) | IDC | 5 | 17 | 1.00 |
LDC | 0 | 1 | ||
T stage | T1-T2 | 3 | 13 | 0.62 |
T3-T4 | 2 | 5 | ||
N stage | N0-N1 | 4 | 16 | 0.54 |
N2-N3 | 1 | 2 | ||
Histologic grade | Period II A-II B | 3 | 11 | 1.00 |
Period III A-III C | 2 | 7 | ||
ER expression | Positive | 4 | 12 | 1.00 |
Negative | 1 | 6 | ||
PR expression | Positive | 3 | 6 | 0.34 |
Negative | 2 | 12 | ||
HER2 expression | 0-2+ | 5 | 10 | 0.12 |
3+ | 0 | 8 | ||
Ki-67 expression | ≥20% | 3 | 13 | 0.62 |
<20% | 2 | 5 | ||
Blood TILs ratio (%, mean ± SD) | ||||
CD3+TILs | 69.34 ± 9.25 | 73.78 ± 8.63 | 0.23 | |
CD4+TILs | 36.12 ± 3.95 | 41.39 ± 6.94 | 0.04 | |
CD8+TILs | 23.92 ± 3.39 | 24.60 ± 6.37 | 1.00 | |
CD4+/CD8+TILs | 1.54 ± 0.35 | 1.77 ± 0.42 | 0.22 | |
Therapy | ||||
Cyclophosphamide-containing chemotherapy regimen | Yes | 5 | 18 | / |
No | 0 | 0 | ||
Anthracycline-containing chemotherapy | Yes | 3 | 12 | 1.000 |
No | 2 | 6 | ||
Taxol-containing chemotherapy | Yes | 4 | 14 | 1.000 |
No | 1 | 4 | ||
Herceptin targeted therapy | Yes | 5 | 10 | 0.12 |
No | 0 | 8 | ||
Chemotherapy cycle | ≤6 cycles | 4 | 14 | 1.000 |
>6 cycles | 1 | 4 | ||
Chemotherapy interval | Intensive chemotherapy | 1 | 3 | 1.000 |
Conventional chemotherapy | 4 | 15 |
IDC, invasive ductal carcinoma; LDC, invasive lobular carcinoma; TILs, tumor infiltrating lymphocytes.
Tumors were categorized as ER, PR, HER2, and Ki-67 based on immunohistochemical testing results. If HER2 immunohistochemical testing result is 2+, two-probe method FISH is required.
Bolded values indicate the significant results.